CTNNB1 Knockout HEK293 Cell Line

The choice depends on whether you are studying CTNNB1 (β-catenin)'s role as the principal effector of canonical Wnt signaling or modeling β-catenin-mutant cancers and developmental disorders. The Knockout line is the standard tool for asking whether β-catenin is required for these processes — β-catenin has dual functions: structural (E-cadherin-mediated cell-cell adhesion at adherens junctions) and signaling (canonical Wnt pathway effector); in the absence of Wnt, β-catenin is targeted by the destruction complex (APC, AXIN, GSK3β, CK1α) for proteasomal degradation; Wnt signaling stabilizes β-catenin, allowing nuclear translocation and TCF/LEF-mediated transcription. Overexpression of wild-type β-catenin shows modest stabilization; overexpression of activating mutants (S33, S37, T41, S45 phospho-degron mutants) drives strong gain-of-function. For Wnt signaling research, the EDITGENE CTNNB1 Knockout in HEK293 is a workhorse mechanistic platform — HEK293 supports systematic structure-function studies. Rescue with wild-type, exon 3 phospho-degron mutants (S33Y, S37F, T41A, S45F — common in hepatocellular carcinoma, colorectal cancer, endometrial cancer, Wilms tumor, desmoid tumor), or DNA-binding-deficient β-catenin enables comprehensive structure-function and disease modeling. The knockout is valuable for studying Wnt pathway biology, β-catenin-driven cancer mechanisms, and emerging Wnt-targeted therapeutics (porcupine inhibitors LGK974/WNT974, β-catenin/TCF inhibitors PRI-724, BC2059).

Primary applications: • Canonical Wnt signaling: TCF/LEF reporter assays, AXIN2/LGR5/MYC target gene expression following Wnt3a stimulation in β-catenin-null cells. • β-catenin destruction complex: APC, AXIN1, GSK3β interaction analysis and β-catenin S33/S37/T41/S45 phospho-degron biology. • Cancer mutation rescue: S33Y, S37F, T41A, S45F exon 3 phospho-degron mutations enable HCC, CRC, endometrial, Wilms tumor, desmoid tumor disease modeling. • E-cadherin adhesion: β-catenin's role in adherens junction maintenance through E-cadherin C-terminus binding. • Wnt-targeted therapy specificity: critical genetic control for porcupine inhibitors (LGK974/WNT974), β-catenin/TCF inhibitors (PRI-724, BC2059) in cancer drug development. EDITGENE recommends this model as the gold-standard genetic null for Wnt signaling research and Wnt-targeted cancer therapeutic development.

Yes. β-catenin rescue experiments are uniquely powerful for Wnt signaling research: • Construct design: use a codon-modified CTNNB1 sequence with a small C-terminal tag (FLAG, HA). β-catenin has N-terminal phospho-degron (S33/S37/T41/S45), central armadillo repeats (TCF/LEF, E-cadherin binding), and C-terminal transactivation domain — preserve all elements. • Constitutively-active rescue: S33Y, S37F, T41A, S45F or Δexon3 mutations bypass GSK3β phosphorylation and destruction complex degradation, generating stable β-catenin — gold-standard for separating Wnt-induced from constitutive β-catenin functions. • Cancer mutation rescue: same exon 3 mutations are common in HCC, CRC, endometrial cancer, Wilms tumor — invaluable for disease modeling. • DNA-binding/TCF-interaction-deficient rescue: armadillo repeat mutations disrupt TCF/LEF binding for separation of transcriptional from junctional functions. • Functional readout: rescue should restore β-catenin-dependent TCF/LEF reporter activity and E-cadherin junctional staining. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.